ANI Pharmaceuticals (ANIP) Expected to Announce Quarterly Earnings on Friday

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) is projected to announce its earnings results before the market opens on Friday, February 28th. Analysts expect the company to announce earnings of $1.41 per share and revenue of $175.36 million for the quarter. Parties that are interested in registering for the company's conference call can do so using this link.

ANI Pharmaceuticals Stock Down 2.9 %

ANIP traded down $1.73 during trading on Friday, hitting $57.94. 218,474 shares of the company's stock were exchanged, compared to its average volume of 161,837. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals has a fifty-two week low of $52.50 and a fifty-two week high of $70.81. The stock has a market cap of $1.22 billion, a P/E ratio of -105.35 and a beta of 0.74. The business's 50 day moving average is $57.08 and its two-hundred day moving average is $58.23.

Insider Activity

In related news, CEO Nikhil Lalwani sold 33,481 shares of the firm's stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the completion of the sale, the chief executive officer now owns 370,378 shares in the company, valued at approximately $21,478,220.22. This trade represents a 8.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Krista Davis sold 1,000 shares of the business's stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the transaction, the senior vice president now owns 49,059 shares in the company, valued at approximately $2,943,540. The trade was a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 42,781 shares of company stock valued at $2,465,372 in the last ninety days. 12.70% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a report on Wednesday, December 11th. They issued an "outperform" rating and a $80.00 target price on the stock. StockNews.com raised ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday, February 5th. HC Wainwright reissued a "buy" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Finally, Leerink Partnrs raised ANI Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, December 11th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, ANI Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $77.71.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.